Michelle W Wong-Brown

List of Publications by Year
in descending order

19 papers	1,097 citations	758635 12 h-index	794141 19 g-index
21 all docs	21 docs citations	21 times ranked	2399 citing authors

#	Article	IF	Citations
1	BCL-2 family isoforms in apoptosis and cancer. Cell Death and Disease, 2019, 10, 177.	2.7	394
2	Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. Journal of Clinical Oncology, 2016, 34, 1455-1459.	0.8	154
3	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 150, 71-80.	1.1	103
4	No evidence that protein truncating variants inBRIP1are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	1.5	94
5	The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis, 2014, 35, 586-596.	1.3	67
6	DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. Scientific Reports, 2016, 6, 33435.	1.6	56
7	Novel genes associated with lymph node metastasis in triple negative breast cancer. Scientific Reports, 2015, 5, 15832.	1.6	48
8	Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Research, 2015, 17, 111.	2.2	36
9	Reevaluation of the BRCA2 truncating allele c.9976Aâ€‰>â€‰T (p.Lys3326Ter) in a familial breast cancer context. Scientific Reports, 2015, 5, 14800.	1.6	26
10	Mutations in RECQL are not associated with breast cancer risk in an Australian population. Nature Genetics, 2018, 50, 1346-1348.	9.4	19
11	Reevaluation of RINT1 as a breast cancer predisposition gene. Breast Cancer Research and Treatment, 2016, 159, 385-392.	1.1	16
12	The presence of the intron 3 16 bp duplication polymorphism ofp53(rs17878362) in breast cancer is associated with a low Î”40p53:p53 ratio and better outcome. Carcinogenesis, 2016, 37, 81-86.	1.3	16
13	Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 5993.	1.7	15
14	Low prevalence of germline PALB2 mutations in Australian tripleâ€negative breast cancer. International Journal of Cancer, 2014, 134, 301-305.	2.3	13
15	Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study. Npj Breast Cancer, 2021, 7, 76.	2.3	12
16	Methyl-Donor and Cofactor Nutrient Intakes in the First 2â€“3 Years and Global DNA Methylation at Age 4: A Prospective Cohort Study. Nutrients, 2018, 10, 273.	1.7	11
17	When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans. Hereditary Cancer in Clinical Practice, 2016, 14, 6.	0.6	6
18	Global DNA methylation and cognitive and behavioral outcomes at 4 years of age: A crossâ€sectional study. Brain and Behavior, 2020, 10, e01579.	1.0	6

#	Article	IF	Citations
19	Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy. BMC Cancer, 2022, 22, 100.	1.1	4